EG-2201

Last updated
EG-2201
EG-2201.svg
Names
IUPAC name
[9-(5-fluoropentyl)carbazol-3-yl]-naphthalen-1-ylmethanone
Other names
(9-(5-fluoropentyl)-9H-carbazol-3-yl)(naphthalen-1-yl)methanone
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
UNII
  • InChI=1S/C28H24FNO/c29-17-6-1-7-18-30-26-14-5-4-12-23(26)25-19-21(15-16-27(25)30)28(31)24-13-8-10-20-9-2-3-11-22(20)24/h2-5,8-16,19H,1,6-7,17-18H2
    Key: LYDDINAZVHIBGP-UHFFFAOYSA-N
  • C1=CC=C2C(=C1)C=CC=C2C(=O)C3=CC4=C(C=C3)N(C5=CC=CC=C54)CCCCCF
Properties
C28H24FNO
Molar mass 409.504 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN (what is  Yes check.svgYX mark.svgN ?)

EG-2201 (also known as NA-5F-PCZMO using EUDA systematic nomenclature [1] ) is a synthetic cannabinoid derived from a carbazole core group. [2] It has been identified as a designer drug and is structurally related to other synthetic cannabinoids, such as EG-018 and MDMB-CHMCZCA. It is primarily used illicitly due to its psychoactive effects, which mimic delta-9-tetrahydrocannabinol (THC), the active ingredient in cannabis. [3]

Contents

Chemical properties

EG-2201 comprises a carbazole core group with a 5-fluoropentyl tail group, a methanone linker group, and a napthylenyl linked group. The use of a carbazole core group may increase CB2 receptor affinity compared to less bulky core groups like indoles and indazoles. [3] [4]

Pharmacology

EG-2201 acts as an agonist of both human cannabinoid receptors, CB1 and CB2, at an affinity of 22.4 ± 12.8 nM and 4.36 ± 2.91 nM, respectively. [4]

Risks and toxicity

Limited toxicity studies exist for EG-2201, but related synthetic cannabinoids are associated with seizures, cardiovascular events, and psychiatric disturbances. Its metabolic byproducts may also be toxic. [5]

See also

References

  1. ↑ Pulver B, Fischmann S, Gallegos A, Christie R (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis. 15 (3): 255–276. doi:10.1002/dta.3403. PMID   36346325. S2CID   253396419.
  2. ↑ Mogler, Lukas; Franz, Florian; Wilde, Maurice; Huppertz, Laura M.; Halter, Sebastian; Angerer, Verena; Moosmann, Bjoern; Auwärter, Volker (2018). "Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples" . Drug Testing and Analysis. 10 (9): 1417–1429. doi:10.1002/dta.2398. ISSN   1942-7611. PMID   29726116.
  3. 1 2 Potts, A. J.; Cano, C.; Thomas, S. H. L.; Hill, S. L. (2020-02-01). "Synthetic cannabinoid receptor agonists: classification and nomenclature" . Clinical Toxicology. 58 (2): 82–98. doi:10.1080/15563650.2019.1661425. ISSN   1556-3650. PMID   31524007.
  4. 1 2 Schoeder, Clara T.; Hess, Cornelius; Madea, Burkhard; Meiler, Jens; Müller, Christa E. (16 April 2017). "Pharmacological evaluation of new constituents of "Spice": synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds". Forensic Toxicology. 36 (2): 385–403. doi: 10.1007/s11419-018-0415-z . ISSN   1860-8965. PMC   6002460 . PMID   29963207.
  5. ↑ Banister, Samuel D.; Connor, Mark (2018), Maurer, Hans H.; Brandt, Simon D. (eds.), "The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution" , New Psychoactive Substances, vol. 252, Cham: Springer International Publishing, pp. 191–226, doi:10.1007/164_2018_144, ISBN   978-3-030-10560-0, PMID   30105473 , retrieved 2025-01-02
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.